China Interferon Industry Report, 2016-2021
  • Apr.2017
  • Hard Copy
  • USD $2,600
  • Pages:82
  • Single User License
    (PDF Unprintable)       
  • USD $2,400
  • Code: ZLC047
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,800
  • Hard Copy + Single User License
  • USD $2,800

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepatitis C, while IFN-β is the mainstream medicine for MS which sees a higher incidence in Europe and America than in Asia, so foreign countries usually adopt IFN-β whereas clinical applications in China center on IFN-α.

China where liver diseases prevail has maintained the demand for interferon worth more than RMB4 billion in recent years, of which hepatitis B-use interferon accounts for over 60% of the entire interferon market. However, the hepatitis B-use interferon market rapidly shrank in 2016 under the impact of the expired patented drugs, the substitution of nucleoside drugs and other factors, resulting in the sharp year-on-year decline of 50.4% in the interferon revenue (RMB361 million) of Chinese sample hospitals in 2016; it was estimated that Chinese interferon market size hit about RMB2.22 billion in the whole 2016.

It is expected that Chinese interferon market will be hard to turn the declining situation around in the next few years. Both of the sluggish hepatitis B-use interferon market and the launch of DAAs drugs will make the hepatitis C-use interferon market suffer a crisis. At present, the overseas hepatitis C-use interferon market has been significantly affected by DAAs drugs and slumped. Although DAAs drugs are not available in China, more than 30 companies have filed for DAAs drugs and DAAs drugs are expected to be revealed in this country within 2 years, which will impact the domestic interferon market once again then.

In recent years, Chinese interferon market is mainly occupied by Roche and MSD, which seize more than 60% market share together, while local Chinese peers represented by Anke Biotechnology, Kawin Technology and Tri-Prime Gene grasp no more than 5% apiece. But in 2016, the contracted hepatitis B-use interferon market dramatically dragged down the combined market share of Roche and MSD to about 40%.


Interferon is mainly divided into ordinary interferon and long-acting interferon. Compared with ordinary interferon which should be injected three times a week, long-acting interferon is injected only once a week, which significantly reduces the patients' medication compliance with less side effect. Yet, Chinese long-acting interferon market has been monopolized by Roche and MSD which offer high prices.

On October 13, 2016, China's first long-acting interferon developed by Amoytop Biotech with independent intellectual property rights obtained the approval for the launch, breaking the monopoly of foreign enterprises. Moreover, Anke Biotechnology, Tri-Prime Gene, Chia Tai Tianqing and other companies are developing long-acting interferon. In the future, the competition in Chinese long-acting interferon market will prick up, which will further squeeze the market share of Roche and MSD.

The report mainly covers the following:
20120114.gifOverview of China interferon industry, including development process, status quo, market size, market structure and competitive landscape;
20120114.gifAnalysis on China interferon market segments, especially in-depth analysis on market size, competitive landscape and prices of ordinary interferon and long-acting interferon;
20120114.gifAnalysis on the downstream market of China interferon industry, including status quo and development trend of hepatitis B, hepatitis C and pediatric markets;
20120114.gifOperation and interferon business of 17 domestic and 2 foreign interferon enterprises;
20120114.gifSummary and forecast.

1 Overview
1.1 Definition
1.2 Classification

2 Overview of China Interferon Industry
2.1 Development Course
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape

3 China Interferon Market Segments
3.1 Ordinary Interferon 
3.1.1 Introduction 
3.1.2 Market Size
3.1.3 Competitive Landscape
3.1.4 Price Comparison
3.2 Long-acting Interferon 
3.2.1 Introduction 
3.2.2 Market Size 
3.2.3 Competitive Landscape
3.2.4 Price Comparison 

4 Downstream Market of China Interferon Industry
4.1 Hepatitis B 
4.1.1 Introduction 
4.1.2 Therapy 
4.1.3 Interferon Hepatitis B Market Shrinks
4.1.4 Market Size 
4.2 Hepatitis C 
4.2.1 Introduction 
4.2.2 Therapy 
4.2.3 The Launch of DAAs Drugs Impacts Chinese Interferon Hepatitis C Market
4.3 Pediatrics
4.4 Others

5 Major Chinese Enterprises
5.1 Anke Biotechnology 
5.1.1 Profile  
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 R & D and Investment 
5.1.5 Interferon Business 
5.1.6 Forecast and Prospect 
5.2 Tri-Prime Gene 
5.2.1 Profile  
5.2.2 Operation 
5.2.3 R & D 
5.2.4 Major Customers 
5.2.5 Interferon Business 
5.2.6 Forecast and Prospect 
5.3 Kawin Technology 
5.3.1 Profile  
5.3.2 Operation 
5.3.3 Revenue Structure 
5.3.4 R & D and Investment 
5.3.5 Major Customers 
5.3.6 Interferon Business 
5.3.7 Forecast and Prospect 
5.4 Amoytop Biotech 
5.4.1 Profile  
5.4.2 Operation 
5.4.3 Interferon Business 
5.5 Shenzhen Kexing Biotech 
5.5.1 Profile  
5.5.2 Interferon Business 
5.6 Sinobioway Biomedicine 
5.6.1 Profile  
5.6.2 Interferon Business 
5.7 3SBio 
5.7.1 Profile  
5.7.2 Operation 
5.7.3 Interferon Business 
5.8 Harbin Pharmaceutical Group Bioengineering 
5.8.1 Profile 
5.8.2 Operation 
5.8.3 Interferon Business 
5.9 Changchun Institute of Biological Products Co., Ltd. 
5.9.1 Profile 
5.9.2 Interferon Business 
5.10 Zhejiang Hansheng Pharmaceutical Co., Ltd. of Beisheng Pharma
5.10.1 Profile  
5.10.2 Interferon Business 
5.11 Others
5.11.1 Hainan Xinmingda Biopharmaceutical Co., Ltd
5.11.2 Beijing Yuance Pharmaceutical Co., Ltd.
5.11.3 Heilongjiang Qingfengyuan Biological Engineering Technology Co., Ltd
5.11.4 Liaoning Satellite Institute of Biological Products Co., Ltd.
5.11.5 Shanghai Chemo Wanbang Biopharma Co., Ltd
5.11.6 Changchun Heber Biological Technology Co., Ltd 
5.11.7 Shanghai Huaxin High Biotechnology Inc. 

6 Major Foreign Companies
6.1 Roche
6.1.1 Profile  
6.1.2 Operation 
6.1.3 Revenue Structure 
6.1.4 Interferon Business 
6.1.5 Development in China 
6.2 MSD 
6.2.1 Profile 
6.2.2 Operation 
6.2.3 Revenue Structure 
6.2.4 Interferon Business 
6.2.5 Development in China 

7 Summary and Forecast
Classification and Characteristics of Interferon
Development Course of Interferon Drugs
Market Size of Chinese Medicine for Liver Disease Treatment, 2010-2016
Market Structure of Chinese Medicine for Liver Disease Treatment, 2015 
Interferon Revenue and YoY Growth Rate of Chinese Sample Hospitals, 2012-2016
Interferon Revenue of Chinese Sample Hospitals (by Type), 2012-2016
Interferon Revenue of Chinese Sample Hospitals (by Product), 2012-2016
China’s Interferon Market Size, 2012-2016
China’s Interferon Market Structure (by Type), 2013-2016
China’s Interferon Market Structure (by Product), 2013-2016
Market Share in China Interferon Industry (by Company), 2015
Market Share in China Interferon Industry (by Company), 2016
Ordinary Interferon Revenue of Chinese Sample Hospitals, 2012-2016
China’s Ordinary Interferon Market Size, 2012-2016
Ordinary Interferon Market Share in China (by Company), 2015
Product Specifications and the Latest Bid Prices of Major Ordinary Interferon Enterprises in China
Registration and Approval of Long-acting Interferon in China
Long-acting Interferon Revenue of Chinese Sample Hospitals, 2012-2016 
Long-acting Interferon Revenue of Chinese Sample Hospitals (by Product), 2012-2016
China’s Long-acting Interferon Market Size, 2012-2016
Long-acting Interferon Revenue of Chinese Sample Hospitals (by Company), 2012-2016
China’s Long-acting Interferon Market Share (by Company), 2012-2016
Major Long-acting Interferon R & D Enterprises in China and Their Product R & D Progress, 2016
Product Specifications and Bid Prices of Long-acting Interferon Enterprises in China,2016
Market Size of Anti-Hepatitis B Virus Drugs in China, 2013-2016
Major Drugs for Hepatitis B Treatment and Their Function in China
Comparison between Main Nucleoside Drugs in China
Share of Hepatitis B Antiviral Drugs in Chinese Sample Hospitals, 2010-2016
China’s Hepatitis B-use Interferon Market Size, 2013-2016
China’s Annual Hepatitis C Incidence, 2008-2016
Development Course of Anti-Hepatitis C Drugs 
Launched New-type Anti-Hepatitis C Drugs Worldwide, 2013-2016
Main New-type Anti-Hepatitis C Drugs in Research Worldwide, 2016    
Application for New-type Anti-Hepatitis C Drugs in China, 2016
China’s AIDS Incidence, 2011-2016
China’s AIDS Death Toll, 2011-2016
Development Course of Anke Biotechnology 
Revenue and Net Income of Anke Biotechnology, 2013-2016
Revenue of Anke Biotechnology (by Product), 2013-2016
Revenue Structure of Anke Biotechnology (by Product), 2013-2016
R & D Costs and % of Total Revenue of Anke Biotechnology, 2013-2016
Interferon Products of Anke Biotechnology
Interferon Product Specifications of Anke Biotechnology 
Interferon Revenue of Anke Biotechnology, 2013-2016
Revenue and Net Income of Anke Biotechnology, 2016-2021E 
Revenue and Net Income of Tri-Prime Gene, 2013-2016 
R & D Costs of Tri-Prime Gene, 2013-2016 
Revenue of Tri-Prime Gene from Top 5 Clients, 2014-2016
Interferon Product Specifications of Tri-Prime Gene 
Revenue and Net Income of Tri-Prime Gene, 2015-2021E 
Revenue and Net Income of Kawin Technology, 2013-2015
Revenue Structure of Kawin Technology (by Product), 2013-2015 
Ongoing Research Projects and Progress of Kawin Technology
R & D Costs of Kawin Technology, 2013-2015  
Fund-raising Investment Projects of Kawin Technology 
Revenue of Kawin Technology from Top 5 Clients, 2013-2015
Main Interferon Products of Kawin Technology  
Interferon Product Specifications of Kawin Technology 
Interferon Revenue of Kawin Technology, 2013-2015
Interferon Revenue of Kawin Technology (by Product), 2013-2015
Revenue and Net Income of Kawin Technology, 2015-2021E
Development Course of Amoytop Biotech
Financial Data of Amoytop Biotech, 2013-2016 
Introduction to Amoytop Biotech’s “Paigebin” Long-acting Interferon 
Development Course of Amoytop Biotech’s “Paigebin” Long-acting Interferon
Introduction to Shenzhen Kexing Biotech’s “Sairuojin” Interferon 
Interferon Products of Sinobioway Biomedicine
Interferon Product Specifications of Sinobioway Biomedicine 
3SBio’s Revenue and Net Income, 2014-2016
3SBio’s Interferon Product Specifications 
Revenue and Net Income of Harbin Pharmaceutical Group Bioengineering, 2014-2016 
Main Interferon Products of Harbin Pharmaceutical Group Bioengineering 
Interferon Product Specifications of Harbin Pharmaceutical Group Bioengineering 
Interferon Product Specifications of Changchun Institute of Biological Products Co., Ltd.  
Interferon Product Specifications of Zhejiang Hansheng Pharmaceutical Co., Ltd. of Beisheng Pharma 
Interferon Product Specifications of Hainan Xinmingda Biopharmaceutical Co., Ltd 
Interferon Product Specifications of Beijing Yuance Pharmaceutical Co., Ltd. 
Interferon Product Specifications of Heilongjiang Qingfengyuan Biological Engineering Technology Co., Ltd 
Interferon Product Specifications of Liaoning Satellite Institute Of Biological Products Co., Ltd. 
Interferon Product Specifications of Shanghai Chemo Wanbang Biopharma Co., Ltd 
Interferon Product Specifications of Changchun Heber Biological Technology Co., Ltd 
Interferon Product Specifications of Shanghai Huaxin High Biotechnology Inc. 
Revenue and Net Income of Roche, 2013-2016
Revenue Breakdown of Roche (by Division), 2013-2016
Revenue Structure of Roche (by Division), 2013-2016
Revenue Breakdown of Roche’s Pharma Division (by Region), 2013-2016
Revenue Structure of Roche’s Pharma Division (by Region), 2013-2016
Revenue Breakdown of Roche’s Diagnosis Division (by Business), 2013-2016
Revenue Structure of Roche’s Diagnosis Division (by Business), 2013-2016
Roche’s Pegasys Revenue and % of Total Revenue, 2013-2016
Roche’s Pegasys Revenue (by Region), 2013-2015
Roche’s Pegasys Sales in Chinese Sample Hospitals, 2013-2016
Revenue and Net Income of MSD, 2013-2016
Revenue Breakdown of MSD (by Product), 2013-2016
Revenue Structure of MSD (by Product), 2013-2016
Revenue Breakdown of MSD (by Region), 2013-2016
Revenue Structure of MSD (by Region), 2013-2016
MSD’s Peg-Intron Revenue and % of Total Revenue, 2013-2015
Development Course of MSD in China
MSD’s Peg-Intron Sales in Chinese Sample Hospitals, 2012-2016
China Interferon Market Size, 2016-2021E
R&D of Key Long-acting Interferon in China, 2016
Interferon Market Structure (by Type) in China, 2016-2021E
Interferon Market Size (by Type) in China, 2016-2021E

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号